BioLife Solutions Inc. (BLFS)

16.19
NASDAQ : Health Technology
Prev Close 16.93
Day Low/High 16.04 / 16.93
52 Wk Low/High 9.15 / 26.35
Avg Volume 176.20K
Exchange NASDAQ
Shares Outstanding 18.80M
Market Cap 318.27M
EPS 0.20
P/E Ratio 80.62
Div & Yield N.A. (N.A)

Latest News

BioLife Solutions To Join Russell 3000® Index

BioLife Solutions To Join Russell 3000® Index

BOTHELL, Wash., June 10, 2019 /PRNewswire/ --   BioLife Solutions , Inc.

BioLife Solutions To Present At The Jefferies 2019 Healthcare Conference

BioLife Solutions To Present At The Jefferies 2019 Healthcare Conference

BOTHELL, Wash., May 30, 2019 /PRNewswire/ --  BioLife Solutions , Inc.

BioLife Solutions Announces SAVSU Technologies Selected By Novartis To Supply Advanced Cold Chain Management Platform For Newly Approved Gene Therapy

BioLife Solutions Announces SAVSU Technologies Selected By Novartis To Supply Advanced Cold Chain Management Platform For Newly Approved Gene Therapy

Cloud-Connected, Smart Shippers and evo.is Real-Time Visibility Platform Improve Quality of Transportation and Delivery of Lifesaving Therapies

BioLife Solutions Announces First Quarter 2019 Financial Results

BioLife Solutions Announces First Quarter 2019 Financial Results

- Revenue Increased 51% to a Record $5.8 million

BioLife Solutions To Report First Quarter 2019 Financial Results And Provide Business Update On May 9, 2019

BioLife Solutions To Report First Quarter 2019 Financial Results And Provide Business Update On May 9, 2019

BOTHELL, Wash., May 2, 2019 /PRNewswire/ --  BioLife Solutions, Inc.

BioLife Solutions Completes Acquisition Of Astero Bio

BioLife Solutions Completes Acquisition Of Astero Bio

Gains products that automate the thawing process for high-value biologic therapies

Biolife Solutions Reaches Analyst Target Price

Biolife Solutions Reaches Analyst Target Price

In recent trading, shares of Biolife Solutions Inc have crossed above the average analyst 12-month target price of $20.00, changing hands for $20.51/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

BioLife Solutions Announces Fourth Quarter And Full Year 2018 Financial Results

BioLife Solutions Announces Fourth Quarter And Full Year 2018 Financial Results

Revenue Increased 79% for the Year to $19.7 Million

BioLife Solutions Expands Cell And Gene Therapy Tools Portfolio With Acquisition Of Astero Bio

BioLife Solutions Expands Cell And Gene Therapy Tools Portfolio With Acquisition Of Astero Bio

Gains products that automate the thawing process for high-value biologic therapies

BioLife Solutions To Report Fourth Quarter And Full Year 2018 Financial Results And Provide Business Update On March 14, 2019

BioLife Solutions To Report Fourth Quarter And Full Year 2018 Financial Results And Provide Business Update On March 14, 2019

BOTHELL, Wash., March 4, 2019 /PRNewswire/ --  BioLife Solutions, Inc.

Bullish Two Hundred Day Moving Average Cross - BLFS

Bullish Two Hundred Day Moving Average Cross - BLFS

In trading on Thursday, shares of Biolife Solutions Inc crossed above their 200 day moving average of $13.81, changing hands as high as $14.36 per share. Biolife Solutions Inc shares are currently trading up about 8.5% on the day.

SAVSU Technologies Launches Two New Evo® Smart Shipper Models To Improve Apheresis Collection Shipments And Cryopreserved Cell And Gene Therapies

SAVSU Technologies Launches Two New Evo® Smart Shipper Models To Improve Apheresis Collection Shipments And Cryopreserved Cell And Gene Therapies

evo ACS™ Extends Thermal Protection During Shipment of Patients' T Cells for Downstream Manufacturing of CAR T-Cell Therapies

New Policies To Advance Development Of Cell And Gene Therapies Announced By FDA

New Policies To Advance Development Of Cell And Gene Therapies Announced By FDA

FDA Cites Increases in IND Submissions and Anticipated Product Approvals that could benefit BioLife Solutions

Biolife Solutions Breaks Above 200-Day Moving Average - Bullish For BLFS

Biolife Solutions Breaks Above 200-Day Moving Average - Bullish For BLFS

In trading on Monday, shares of Biolife Solutions Inc crossed above their 200 day moving average of $13.26, changing hands as high as $13.52 per share. Biolife Solutions Inc shares are currently trading up about 11.5% on the day.

Biolife Solutions Enters Oversold Territory (BLFS)

Biolife Solutions Enters Oversold Territory (BLFS)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BLFS, BOSC, HESM, PLAB, PSEC Downgrades: CREE, IMMU Initiations: FPH, RNGR Read on to get TheStreet Quant Ratings' detailed report:

Biolife Solutions Reaches Analyst Target Price

Biolife Solutions Reaches Analyst Target Price

In recent trading, shares of Biolife Solutions Inc have crossed above the average analyst 12-month target price of $20.00, changing hands for $20.81/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

BLFS Crosses Above Average Analyst Target

BLFS Crosses Above Average Analyst Target

In recent trading, shares of Biolife Solutions Inc have crossed above the average analyst 12-month target price of $11.50, changing hands for $14.99/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Biolife Solutions Reaches Analyst Target Price

Biolife Solutions Reaches Analyst Target Price

In recent trading, shares of Biolife Solutions Inc have crossed above the average analyst 12-month target price of $10.67, changing hands for $10.71/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Biolife Solutions Reaches Analyst Target Price

Biolife Solutions Reaches Analyst Target Price

In recent trading, shares of Biolife Solutions Inc have crossed above the average analyst 12-month target price of $5.75, changing hands for $5.81/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

BLFS Crosses Above Average Analyst Target

BLFS Crosses Above Average Analyst Target

In recent trading, shares of Biolife Solutions Inc have crossed above the average analyst 12-month target price of $5.08, changing hands for $5.29/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Shark Bites: Drone Maker AeroVironment Lines Up for 'Doofus' Trade

Shark Bites: Drone Maker AeroVironment Lines Up for 'Doofus' Trade

An attractive pattern has formed for AVAV.

These 5 Stocks Under $10 Could Make You a Lot of Money

These 5 Stocks Under $10 Could Make You a Lot of Money

Here's a technical look at how to trade several under-$10 stocks that are within range of triggering big breakouts.

BioLife Solutions (BLFS) Is Strong On High Volume Today

BioLife Solutions (BLFS) Is Strong On High Volume Today

Trade-Ideas LLC identified BioLife Solutions (BLFS) as a strong on high relative volume candidate

BioLife Solutions (BLFS) Weak On High Volume

BioLife Solutions (BLFS) Weak On High Volume

Trade-Ideas LLC identified BioLife Solutions (BLFS) as a weak on high relative volume candidate

Strong On High Volume: BioLife Solutions (BLFS)

Strong On High Volume: BioLife Solutions (BLFS)

Trade-Ideas LLC identified BioLife Solutions (BLFS) as a strong on high relative volume candidate

BioLife Sciences (BLFS) Stock Spikes as Clinical Trial Meets Primary Endpoint

BioLife Sciences (BLFS) Stock Spikes as Clinical Trial Meets Primary Endpoint

BioLife Sciences (BLFS) shares are up over 60% to after customer TiGenix's clinical trial meets primary endpoint.

TheStreet Quant Rating: C (Hold)